CLIA TBE Virus IgG

Chemiluminescence kit for the detection of IgG antibodies to Tick-borne encephalitis virus in human serum or plasma.

New
Catalog Number: CL-TBG100
Size: 100 tests
Regulatory status: CE IVD
Clinical topic: Infectious Diseases
Diagnostic panel: Tick-Borne Infections
Vaccination Monitoring
CLIA TBE Virus IgG
  • Detection of IgG antibodies to Tick-Borne Encephalitis Virus (TBEV)
  • Determination of IgG antibodies avidity to differentiate various stages of infection
  • Checking the effectiveness of vaccination
  • Intended for human serum, plasma
  • Purified and inactivated native TBEV antigen used

Tick-borne encephalitis (TBE) is a viral infectious disease caused by an arbovirus from the family Flaviviridae. The infection is characterized by a natural focal distribution. Reservoir hosts of the virus are forest animals, humans are infected through tick bites. Most TBE cases occur from summer to autumn. Up to 70 % of TBE infections are clinically inapparent. If manifested, the illness non-specific flu-like symptoms occur after an incubation period (3-14 days). After several days of remission, the second (neurologic) phase of the disease develops. An acute stage of tick-borne encephalitis lasts 1 to 3 weeks. More severe course of the disease, often with lasting ill effects, can be observed in senior patients.

The diagnosis of tick-borne encephalitis is based on anamnesis, clinical picture, and results of laboratory tests, which include biochemical and cytological investigation of liquor and serological detection of specific IgM and IgG antibodies in serum. The IgM antibodies are the serological marker of acute infection and their production can last up to 10 months. The IgG antibodies protect the organism against a new infection, and they can be detected over several years after the past infection or vaccination. The IgG avidity determination improves the detection of the current phase of the infection. Borderline results should be verified by virus neutralization test (VNT).

Technical specifications

Technical data
References
Related Products
Downloads

Technical data

Assay time30 min
Sample matrix Serum, Plasma
Sample volume10 µL
Sample stability7 days at 2-8 °C, 24 months at -20 °C
Concentration range3 - 600 U/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions

References

References to CLIA TBE Virus IgG

  • Riccardi N, Antonello RM, Luzzati R, Zajkowska J, Di Bella S, Giacobbe DR. Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. Eur J Intern Med. 2019 Apr;62:1-6. doi: 10.1016/j.ejim.2019.01.004. Epub 2019 Jan 22. PMID: 30678880.
    See more on PubMed
  • Taba P, Schmutzhard E, Forsberg P, Lutsar I, Ljøstad U, Mygland Å, Levchenko I, Strle F, Steiner I. EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. Eur J Neurol. 2017 Oct;24(10):1214-e61. doi: 10.1111/ene.13356. Epub 2017 Aug 1. PMID: 28762591.
    See more on PubMed
  • Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008 May 31;371(9627):1861-71. doi: 10.1016/S0140-6736(08)60800-4. PMID: 18514730.
    See more on PubMed
  • Yoshii K. Epidemiology and pathological mechanisms of tick-borne encephalitis. J Vet Med Sci. 2019 Mar 14;81(3):343-347. doi: 10.1292/jvms.18-0373. Epub 2019 Jan 23. PMID: 30674746; PMCID: PMC6451894.
    See more on PubMed
  • Halperin JJ. Diagnosis and management of acute encephalitis. Handb Clin Neurol. 2017;140:337-347. doi: 10.1016/B978-0-444-63600-3.00018-0. PMID: 28187808.
    See more on PubMed

Downloads

Safety information

Declaration of conformity

Find documents for the batch

Do you want to learn more?
We're here for you

Please fill in
all fields
marked *
Up
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Find out more here.
Agree